Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 12/20 | 0.67 |
| ▸ | PTK2B | Q14289 | 4/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.48 |
| ▸ | MET | P08581 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15033860 | 0.91 | ULK1 (0.56) | ULK1PTK2BPTK2 | |
| SCHEMBL15033868 | 0.91 | ULK1 (0.65) | ULK1PTK2BPTK2METCDK1 | |
| SCHEMBL10125509 | 0.91 | ULK1 (0.65) | ULK1PTK2BPTK2METCDK1 | |
| SCHEMBL10125464 | 0.89 | ULK1 (0.85) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL15033827 | 0.83 | ULK1 (0.56) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL15033892 | 0.82 | PTK2 (0.54) | ULK1PTK2BPTK2 | |
| SCHEMBL15033851 | 0.82 | PTK2 (0.54) | ULK1PTK2BPTK2 | |
| SCHEMBL10125386 | 0.81 | ULK1 (0.58) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL15024023 | 0.81 | ULK1 (0.75) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL19654215 | 0.81 | ULK1 (0.75) | ULK1PTK2BPTK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606034-B1 | PYRIMIDINE DERIVATIVE AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-09 | — | — | EP | claimed |
| US-8906916-B2 | Pyrimidine derivatives as FAK inhibitors | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | claimed |
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-20 | — | — | US | claimed |
| EP-2606034-B1 | PYRIMIDINE DERIVATIVE AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-09 | — | — | EP | disclosed |
| EP-2606034-B1 | PYRIMIDINE DERIVATIVE AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-8906916-B2 | Pyrimidine derivatives as FAK inhibitors | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-20 | — | — | US | disclosed |
| WO-2012022408-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | CDK2, PTK2, CDKN1A | ULK1 1675/4885PTK2B 21/4885PTK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.